Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
Adult
Humans
Female
Middle Aged
Immunosuppressive Agents
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
/ complications
Rituximab
/ therapeutic use
Aniline Compounds
/ adverse effects
Glucocorticoids
/ therapeutic use
Antibodies, Antineutrophil Cytoplasmic
Granulomatosis with Polyangiitis
/ drug therapy
Remission Induction
ANCA-associated vasculitis
Acute renal failure
Avacopan
Remission
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
23
10
2022
accepted:
23
02
2023
medline:
13
11
2023
pubmed:
11
4
2023
entrez:
10
4
2023
Statut:
ppublish
Résumé
Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is associated with end-organ damage resulting in significant morbidity and mortality. Most recently, avacopan, an orally administered selective antagonist of the C5a receptor, was approved by the US Food and Drug Administration as an adjunctive treatment of adult patients with severe, active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy including glucocorticoids. This case study describes a 58-year-old Asian female with severe ANCA-associated vasculitis and acute renal failure who responded to adjunctive therapy with avacopan despite being refractory to rituximab and glucocorticoid therapy.
Identifiants
pubmed: 37036661
doi: 10.1007/s40620-023-01614-y
pii: 10.1007/s40620-023-01614-y
pmc: PMC10638159
doi:
Substances chimiques
Immunosuppressive Agents
0
avacopan
O880NM097T
Rituximab
4F4X42SYQ6
Aniline Compounds
0
Glucocorticoids
0
Antibodies, Antineutrophil Cytoplasmic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2365-2370Informations de copyright
© 2023. The Author(s).
Références
Pagnoux C (2016) Updates in ANCA-associated vasculitis. Eur J Rheumatol 3(3):122–133
doi: 10.5152/eurjrheum.2015.0043
pubmed: 27733943
pmcid: 5058451
Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D (2021) ANCA-associated vasculitis: an update. J Clin Med 10:1446
doi: 10.3390/jcm10071446
pubmed: 33916214
pmcid: 8037363
Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L et al (2016) Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS ONE 11(10):e0164646
doi: 10.1371/journal.pone.0164646
pubmed: 27768695
pmcid: 5074546
Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599–609
doi: 10.1056/NEJMoa2023386
pubmed: 33596356
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P et al (2017) Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28(9):2756–2767
doi: 10.1681/ASN.2016111179
pubmed: 28400446
pmcid: 5576933
Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A et al (2020) Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol 2(11):662–671
doi: 10.1002/acr2.11185
pubmed: 33128347
pmcid: 7672305
van Leeuwen JR, Bredewold OW, van Dam LS, Werkman SL, Jonker JT, Geelhoed M et al (2022) Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 7(3):624–628
doi: 10.1016/j.ekir.2021.11.036
pubmed: 35257076
Ennis D, Yeung RSM, Pagnoux C (2020) Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. BMJ Case Rep 13(10):e236236
doi: 10.1136/bcr-2020-236236
pubmed: 33122227
pmcid: 7597477
Gabilan C, Pfirmann P, Ribes D, Rigothier C, Chauveau D, Casemayou A et al (2022) Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep 7(5):1115–1118
doi: 10.1016/j.ekir.2022.01.1065
pubmed: 35570990
pmcid: 9091582
Hakroush S, Tampe B (2022) Tailored use of avacopan in a case with refractory antineutrophil cytoplasmic autoantibody-associated renal vasculitis and concominant complement system activation. Kidney Int Rep 8(2):376–378
doi: 10.1016/j.ekir.2022.10.033
pubmed: 36815109
Qin X, Hu H, Cen J, Wang X, Wan Q, Wei Z (2022) Association between urinary protein-to-creatinine ratio and chronic kidney disease progression: a secondary analysis of a prospective cohort study. Front Med (Lausanne) 9:854300
doi: 10.3389/fmed.2022.854300
pubmed: 35433766
Kimoto Y, Horiuchi T (2022) The complement system and ANCA associated vasculitis in the era of anti-complement drugs. Front Immunol 13:926044
doi: 10.3389/fimmu.2022.926044
pubmed: 35812453
pmcid: 9260009
Raby AC, Holst B, Davies J, Colmont C, Laumonnier Y, Coles B et al (2011) TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur J Immunol 41(9):2741–2752
doi: 10.1002/eji.201041350
pubmed: 21630250
pmcid: 3638321
Ward PA (2009) Functions of C5a receptors. J Mol Med 87(4):375–378
doi: 10.1007/s00109-009-0442-7
pubmed: 19189071
Dick J, Gan PY, Ford SL, Odobasic D, Alikhan MA, Loosen SH et al (2018) C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti- myeloperoxidase glomerulonephritis. Kidney Int Rep 93(3):615–625
doi: 10.1016/j.kint.2017.09.018
Bantis K, Stangou M, Kalpakidis S, Hatziadamou M, Daikidou DV, Lioulios G et al (2021) Systemic complement activation in antineutrophil cytoplasmic antibody-associated vasculitis and necrotizing glomerulonephritis. Nephrology (Carlton) 26(1):30–37
doi: 10.1111/nep.13747
pubmed: 32602136
Gou SJ, Yuan J, Chen M, Yu F, Zhao MH (2013) Circulating complement activation in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 83(1):129–137
doi: 10.1038/ki.2012.313
Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R (2009) C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20(2):289–298
doi: 10.1681/ASN.2008050497
pubmed: 19073822
pmcid: 2637051
Tsai IJ, Lin WC, Yang YH, Tseng YL, Lin YH, Chou CH et al (2019) High concentration of C5a-induced mitochondria-dependent apoptosis in murine kidney endothelial cells. Int J Mol Sci 20(18):4465
doi: 10.3390/ijms20184465
pubmed: 31510052
pmcid: 6770645
Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC (2007) Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 170(1):52–64
doi: 10.2353/ajpath.2007.060573
pubmed: 17200182
pmcid: 1762697
Sahu RK, Xavier S, Chauss D, Wang L, Chew C, Stallcup WB et al (2022) Folic acid-mediated fibrosis is driven by C5a receptor 1-mediated activation of kidney myeloid cells. Am J Physiol Renal Physiol 322(6):F597-610
doi: 10.1152/ajprenal.00404.2021
pubmed: 35379003
pmcid: 9054266
Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y et al (2014) C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25(2):225–231
doi: 10.1681/ASN.2013020143
pubmed: 24179165
Soulsby WD (2022) Journal club review of “Avacopan for the treatment of ANCA-associated vasculitis.” ACR Open Rheumatol 4(7):558–561
doi: 10.1002/acr2.11412
pubmed: 35167187
pmcid: 9274376